IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v30y2012i10p869-885.html
   My bibliography  Save this article

New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses

Author

Listed:
  • Douglas Mapel
  • Melissa Roberts

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death and disability worldwide, but before the development of several new pharmacological treatments little could be done for COPD patients. Recognition that these new treatments could significantly improve the prognosis for COPD patients has radically changed clinical management guidelines from a palliative philosophy to an aggressive approach intended to reduce chronic symptoms, improve quality of life and prolong survival. These new treatments have also sparked interest in COPD cost-effectiveness research. Most COPD cost-effectiveness studies have been based on clinical trial populations, limited to direct medical costs, and used standard analysis methods such as Markov modelling, and they have usually found that newer therapies have favourable cost effectiveness. However, new insights into the clinical progression of COPD bring into question some of the assumptions underlying older analyses. In this review, we examine clinical factors unique to COPD and recent changes in clinical perspectives that have important implications for pharmacoeconomic analyses. The main parameters explored include (i) the high indirect medical costs for COPD and their relevance in assessing the societal benefits of new therapy; (ii) the importance of acute deteriorations in COPD, known as exacerbations, and approaches to modelling the cost benefit of exacerbation reduction; (iii) quality/utility instruments for COPD; (iv) the prevalence of co-morbid conditions and confounding between COPD and co-morbid disease utilization; (v) the limitations of Markov modelling; and (vi) the problem of outliers. Copyright Springer International Publishing Switzerland 2012

Suggested Citation

  • Douglas Mapel & Melissa Roberts, 2012. "New Clinical Insights into Chronic Obstructive Pulmonary Disease and Their Implications for Pharmacoeconomic Analyses," PharmacoEconomics, Springer, vol. 30(10), pages 869-885, October.
  • Handle: RePEc:spr:pharme:v:30:y:2012:i:10:p:869-885
    DOI: 10.2165/11633330-000000000-00000
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/11633330-000000000-00000
    Download Restriction: Access to full text is restricted to subscribers.

    File URL: https://libkey.io/10.2165/11633330-000000000-00000?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Alan Brennan & Stephen E. Chick & Ruth Davies, 2006. "A taxonomy of model structures for economic evaluation of health technologies," Health Economics, John Wiley & Sons, Ltd., vol. 15(12), pages 1295-1310, December.
    2. K Cooper & S C Brailsford & R Davies, 2007. "Choice of modelling technique for evaluating health care interventions," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 58(2), pages 168-176, February.
    3. Maureen Rutten-van Mölken & Jan Oostenbrink & Marc Miravitlles & Brigitta Monz, 2007. "Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 8(2), pages 123-135, June.
    4. Eisner, M.D. & Yelin, E.H. & Trupin, L. & Blanc, P.D., 2002. "The influence of chronic respiratory conditions on health status and work disability," American Journal of Public Health, American Public Health Association, vol. 92(9), pages 1506-1513.
    5. Michael Spencer & Andrew Briggs & Ronald Grossman & Laureen Rance, 2005. "Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease," PharmacoEconomics, Springer, vol. 23(6), pages 619-637, June.
    6. O. Zaniolo & S. Iannazzo & L. Pradelli & M. Miravitlles, 2012. "Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 71-80, February.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Francesco Blasi & Giancarlo Cesana & Sara Conti & Virginio Chiodini & Stefano Aliberti & Carla Fornari & Lorenzo Giovanni Mantovani, 2014. "The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients," PLOS ONE, Public Library of Science, vol. 9(6), pages 1-8, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Petra Menn & Reiner Leidl & Rolf Holle, 2012. "A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease," PharmacoEconomics, Springer, vol. 30(9), pages 825-840, September.
    2. Maureen Rutten-van Mölken & Lucas Goossens, 2012. "Cost Effectiveness of Pharmacological Maintenance Treatment for Chronic Obstructive Pulmonary Disease," PharmacoEconomics, Springer, vol. 30(4), pages 271-302, April.
    3. Marion Rauner & Michaela Schaffhauser-Linzatti & Helmut Niessner, 2012. "Resource planning for ambulance services in mass casualty incidents: a DES-based policy model," Health Care Management Science, Springer, vol. 15(3), pages 254-269, September.
    4. Mehdi Najafzadeh & Carlo A Marra & Larry D Lynd & Mohsen Sadatsafavi & J Mark FitzGerald & Bruce McManus & Don Sin, 2012. "Future Impact of Various Interventions on the Burden of COPD in Canada: A Dynamic Population Model," PLOS ONE, Public Library of Science, vol. 7(10), pages 1-12, October.
    5. Viana, J. & Brailsford, S.C. & Harindra, V. & Harper, P.R., 2014. "Combining discrete-event simulation and system dynamics in a healthcare setting: A composite model for Chlamydia infection," European Journal of Operational Research, Elsevier, vol. 237(1), pages 196-206.
    6. Olivier Ethgen & Baudouin Standaert, 2012. "Population–versus Cohort–Based Modelling Approaches," PharmacoEconomics, Springer, vol. 30(3), pages 171-181, March.
    7. Markus Kraus & Marion Rauner & Sigrun Schwarz, 2010. "Hospital management games: a taxonomy and extensive review," Central European Journal of Operations Research, Springer;Slovak Society for Operations Research;Hungarian Operational Research Society;Czech Society for Operations Research;Österr. Gesellschaft für Operations Research (ÖGOR);Slovenian Society Informatika - Section for Operational Research;Croatian Operational Research Society, vol. 18(4), pages 567-591, December.
    8. O. Zaniolo & S. Iannazzo & L. Pradelli & M. Miravitlles, 2012. "Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 71-80, February.
    9. Bernhard Ultsch & Oliver Damm & Philippe Beutels & Joke Bilcke & Bernd Brüggenjürgen & Andreas Gerber-Grote & Wolfgang Greiner & Germaine Hanquet & Raymond Hutubessy & Mark Jit & Mirjam Knol & Rüdiger, 2016. "Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community," PharmacoEconomics, Springer, vol. 34(3), pages 227-244, March.
    10. Becky Pennington & Alex Filby & Lesley Owen & Matthew Taylor, 2018. "Smoking Cessation: A Comparison of Two Model Structures," PharmacoEconomics, Springer, vol. 36(9), pages 1101-1112, September.
    11. Peter J. Dodd & Jeff J. Pennington & Liza Bronner Murrison & David W. Dowdy, 2018. "Simple Inclusion of Complex Diagnostic Algorithms in Infectious Disease Models for Economic Evaluation," Medical Decision Making, , vol. 38(8), pages 930-941, November.
    12. Jonathan Karnon & James Stahl & Alan Brennan & J. Jaime Caro & Javier Mar & Jörgen Möller, 2012. "Modeling Using Discrete Event Simulation," Medical Decision Making, , vol. 32(5), pages 701-711, September.
    13. K Cooper & R Davies & J Raftery & P Roderick, 2008. "Use of a coronary heart disease simulation model to evaluate the costs and effectiveness of drugs for the prevention of heart disease," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 59(9), pages 1173-1181, September.
    14. Stuart J. Wright & William G. Newman & Katherine Payne, 2019. "Accounting for Capacity Constraints in Economic Evaluations of Precision Medicine: A Systematic Review," PharmacoEconomics, Springer, vol. 37(8), pages 1011-1027, August.
    15. Arielle Anderer & Hamsa Bastani & John Silberholz, 2022. "Adaptive Clinical Trial Designs with Surrogates: When Should We Bother?," Management Science, INFORMS, vol. 68(3), pages 1982-2002, March.
    16. Eren Demir & David Southern, 2017. "Enabling better management of patients: discrete event simulation combined with the STAR approach," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 68(5), pages 577-590, May.
    17. Jen Kruger & Daniel Pollard & Hasan Basarir & Praveen Thokala & Debbie Cooke & Marie Clark & Rod Bond & Simon Heller & Alan Brennan, 2015. "Incorporating Psychological Predictors of Treatment Response into Health Economic Simulation Models," Medical Decision Making, , vol. 35(7), pages 872-887, October.
    18. Sarah Bates & Thomas Bayley & Paul Norman & Penny Breeze & Alan Brennan, 2020. "A Systematic Review of Methods to Predict Weight Trajectories in Health Economic Models of Behavioral Weight-Management Programs: The Potential Role of Psychosocial Factors," Medical Decision Making, , vol. 40(1), pages 90-105, January.
    19. F. Tomini & F. Prinzen & A. D. I. Asselt, 2016. "A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(9), pages 1159-1172, December.
    20. Luis Hernandez & Asli Ozen & Rodrigo DosSantos & Denis Getsios, 2016. "Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease," PharmacoEconomics, Springer, vol. 34(7), pages 681-707, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:30:y:2012:i:10:p:869-885. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.